Dear Readers, It is time to think about the next chapter of The Trip Report. I have decided to take a hiatus from the 2-3 posts/week schedule that we've been on for the last year. I will continue to write but not as frequently or on a predetermined schedule.
Psychedelic News Roundup In Partnership with Lucid News Policy Can Psychedelics Help Save America? A Healthcare and bioethics group at Harvard Law scho…
Zach Haigney
There’s a tactic agreement that safety and efficacy are not going to be the barrier to rolling out psychedelic medicine— but rather, delivery will prov…
Zach Haigney
Field Trip IPO On Tuesday, Field Trip Psychedelics became the third publicly traded psychedelic company with at least a $100 million valuation behind M…
Zach Haigney
Jaguar makes one of the two FDA approved Botanical Drugs
Zach Haigney
On November 3rd Oregon voters will have the chance to vote for Measure 109, a state-regulated psilocybin therapy framework. It is the first state-level…
Zach Haigney
Numinus & Field Trip: A Tale of Two Strategies Announcements from Numinus and Field Trip highlight two different approaches and two different challenge…
Zach Haigney
With COMPASS Pathways' listing and early success on NASDAQ, a clear precedent is set. The premise of psychedelic medicine has been accepted by more ext…
Zach Haigney
See all